Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
Article content
TORONTO — Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) ('Satellos' or the 'Company'), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference taking place in Toronto on May 5 and 6.
Article content
Article content
Satellos Co-founder and CEO Frank Gleeson will provide a presentation on May 5 and along with members of the management team, will participate in one-on-one meetings during the conference.
Article content
2025 Bloom Burton & Co. Healthcare Investor Conference
Format: Presentation and webcast
Presenter: Frank Gleeson, President and CEO
Date: Monday, May 5
Time: 11:30 a.m. ET
Location: Metro Toronto Convention Centre
Article content
The presentation will be available via live webcast on the Events and Presentations page in the Investors section of the Company's website, and a replay will be available following the presentation.
Article content
About Satellos Bioscience Inc.
Article content
Satellos is a clinical-stage drug development company dedicated to developing life-improving medicines to treat degenerative muscle diseases. Satellos has invented SAT-3247 as a first-of-its-kind, orally administered small molecule drug designed to restore skeletal muscle regeneration in degenerative or injury conditions by correcting muscle stem cell polarity. Satellos has generated a body of preclinical evidence with SAT-3247 to support its discovery that correcting muscle stem cell polarity has the potential to restore skeletal muscle regeneration to repair and strengthen muscle that has degenerated or been damaged. SAT-3247 is currently in clinical development as a potential disease-modifying treatment initially for DMD. Additionally, Satellos is leveraging its research and proprietary discovery platform MyoReGenX™, to identify additional degenerative muscle diseases or injury conditions where deficits in muscle regeneration occur that are amenable to therapeutic intervention for future clinical development. For more information, visit www.satellos.com.
Article content
Article content
Article content
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
10 hours ago
- Globe and Mail
‘This is a Chaos Trade,' Says Investor About Palantir Stock
The international storm clouds have grown darker throughout 2025, with geopolitical flashpoints popping up left and right. In part due to these tensions, Palantir Technologies (NASDAQ:PLTR) – which touts its capabilities in the defense and security sectors – recently reached an all-time high this week. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter The company has been riding a supercharged wave of growth, demonstrated in its most recent earnings report. Record revenues and a 'Who's Who' of clientele – including NATO, Qualcomm, and a slew of others – have given investors plenty of confidence in Palantir's ability to continue growing. Of course, the big (perhaps, only) caveat when it comes to Palantir is the company's inflated valuation, which is trading at an EV/EBITDA ratio north of 700x. One investor known by the pseudonym Weebler Finance thinks that the expensive Palantir is appropriate, in no small part because it could be a safe harbor during times of turmoil. 'While Palantir appears overvalued by traditional metrics, its explosive growth trajectory could justify its high multiples if geopolitical catalysts continue,' explains the investor. Weebler points to the company's Maven Smart Systems, a central component of its defense-related AI offerings. Maven has seen its usage double in less than half a year, which the investor notes is a strong indication that sovereign nations are going to increase their engagement with Palantir. 'I believe that this exponential ramp-up reflects growing institutional dependence,' adds Weebler. 'The company is uniquely positioned to actually benefit from crisis-driven demand.' Moreover, the investor notes that Palantir's products become 'deeply wired into core workflows,' meaning that replacing the company is no easy feat. Regarding its valuation, while admittedly expensive, Weebler believes that PLTR's share price can be justified if the company can achieve 75% EBITDA growth year-over-year for 2025. Pointing out that Palantir grew by 210% in 2023 and 120% in 2024, this seems like a reasonable assumption to Weebler – especially given the situation around the world. 'Palantir is a company primly suited to thrive in times of geopolitical turbulence,' concludes Weebler Finance, who rates PLTR a Buy. (To watch Weebler Finance's track record, click here) Wall Street offers a mixed picture when it comes to Palantir. With 3 Buy, 10 Hold, and 4 Sell ratings, PLTR has a consensus Hold (i.e. Neutral) rating. Its 12-month average price target of $104.27 has a downside of ~25%. (See PLTR stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Globe and Mail
13 hours ago
- Globe and Mail
The Average Social Security Benefit Just Reached Its Highest Ever
According to the latest data from the Social Security Administration, the average retired worker gets more than $2,000 per month for the first time ever. This is a sharp increase from 2024, despite a relatively low cost-of-living adjustment. In this video, I'll go through the numbers and discuss why they've become so much higher. *Stock prices used were the morning prices of June 19, 2025. The video was published on June 20, 2025. The $23,760 Social Security bonus most retirees completely overlook If you're like most Americans, you're a few years (or more) behind on your retirement savings. But a handful of little-known "Social Security secrets" could help ensure a boost in your retirement income. One easy trick could pay you as much as $23,760 more... each year! Once you learn how to maximize your Social Security benefits, we think you could retire confidently with the peace of mind we're all after. Join Stock Advisor to learn more about these strategies. View the "Social Security secrets" » The Motley Fool has a disclosure policy. Matthew Frankel is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
Cision Canada
a day ago
- Cision Canada
enCore Energy Announces Filing of Early Warning Report
DALLAS, June 20, 2025 /CNW/ - enCore Energy Corp. (NASDAQ: EU) (TSXV: EU) (the"Company" or "enCore"), America's Clean Energy Company ™, announces that it has disposed of 170,000,000 common shares in the capital of Anfield Energy Inc. (" Anfield") (TSX.V: AEC; OTCQB: ANLDF; FRANKFURT: 0AD) in a private agreement at a price of $0.115 per share for aggregate proceeds of $19,550,000 (Canadian dollars). Immediately following the disposition, enCore holds or controls no common shares of Anfield. The disposition represents a 14.73% decrease in enCore's ownership or control over the outstanding common shares of Anfield on an undiluted basis. enCore does not currently hold or control any securities of Anfield. Since enCore's last early warning report dated January 15, 2024, enCore's holdings have decreased by an approximate 16.02% of the outstanding common shares of Anfield on an undiluted basis. enCore disposed of the shares of Anfield in a private transaction. enCore may, depending on market and other conditions, increase beneficial ownership of the Company's securities, whether in the open market, by privately negotiated agreements or otherwise, subject to a number of factors, including general market conditions and other available investment and business opportunities. The disclosure respecting enCore's shareholdings contained in this news release is made pursuant to National Instrument 62-103 and a report respecting the above disposition will be filed with the applicable securities commissions and will be available for viewing at A copy of the report may also be obtained by contacting Robert Willette, Acting Chief Executive Officer, or at [email protected]. About enCore Energy Corp. enCore Energy Corp., America's Clean Energy Company ™, is committed to providing clean, reliable, and affordable fuel for nuclear energy as the only United States uranium company with multiple central processing plants in operation. enCore operates the 100% owned and operated Rosita CPP in South Texas and the 70/30 joint venture Alta Mesa CPP with Boss Energy Ltd., with enCore operating as the project manager. The enCore team is led by industry experts with extensive knowledge and experience in all aspects of ISR uranium operations and the nuclear fuel cycle. enCore solely utilizes ISR for uranium extraction, a well-known and proven technology co-developed by the leaders at enCore Energy. Following upon enCore's demonstrated success in South Texas, future projects in enCore's planned project pipeline include the Dewey-Burdock project in South Dakota and the Gas Hills project in Wyoming. The Company holds other assets including non-core assets and proprietary databases. enCore is committed to working with local communities and indigenous governments to create positive impact from corporate developments.
